Is there a connection between immunotherapy and cardiovascular events such as MI and stroke? Check out the latest Perspectives on the Science piece in #JoCO by David M. Miller MD, PhD, FAAD, @sophiashalhout, et al. doi.org/10.59449/joco.… #Cancer #Immunotherapy

Explore the latest melanoma therapies and the significant role of anti-LAG3 antibodies with Dr. Miller David M. Miller MD, PhD, FAAD! Learn more about this activity: ow.ly/13yc50Nu3fm #SkinCancerAwareness #Melanoma #immunotherapy #CME #medicaleducation #medlearninggroup

Experience our Complimentary Live Virtual CME/CNE Program featuring NMSC on Monday, 6/5, at 7:30 PM ET with Dr. Miller David M. Miller MD, PhD, FAAD and Dr. Patel! Register now: medlearninggroup.com/cme-programmin… #Immunotherapy #MedicalEducation #VirtualEvent #CME #CNE #MedLearningGroup

David Miller & Sophia Shalhout with MassGeneral Medicine & Mass Eye and Ear, will be giving a session presentation on “StoryboardR: An R package and Shiny application designed to visualize real-world data from clinical patient registries” at #RMed2023. #Rstats ➡️ events.linuxfoundation.org/r-medicine/

Looking forward to hearing from our esteemed panelists Kenneth Y. Tsai and Dr. Michael Migden along with co-chair Dr. Michael K Wong in our upcoming MedscapeLIVE event: na.eventscloud.com/website/51593/ It should make for a great discussion.

Excited for the upcoming #RMed2023. Always one of my favorite events of the year. Looking forward to presenting StoryboardR - An R Package and Shiny Application Designed to Visualize Real-World Data From Clinical Patient Registries with @SophiaShalhout. #Rstats R Medicine

You still have time to join us live from #ASCO23! Learn and earn credit from social media. Watch the stream now.

Thanks MedscapeLIVE for another fantastic event on #immunotherapy and #skincancer. Really enjoyed learning from Kenneth Y. Tsai and Dr. Michael Migden. Great having the inimitable Dr. Michael Wong fielding questions on the real-time virtual forum.

Looking forward to discussing the latest developments in the treatment of #NMSC with Dr. Vishal Patel of GW med at tonight’s Med Learning Group event.

🎉 The excitement is building as we count down for our Complimentary Virtual CME/CNE Program on NMSC! Join Dr. Miller David M. Miller MD, PhD, FAAD and Dr. Patel TONIGHT at 7:30 PM EST! Register Now: ow.ly/HZUo50OBUVO #oncology #MedTwitter #VirtualEvent #CME #CNE #MedLearningGroup

Thx to Laura Ferris, Nikhi Khushalani, Kevin Emerick, Sonia Cohen, Sameer Gupta, Ryan Sullivan, Linette Bosques, Emily Kim, MD, @BhatiaS_MD, @MunTheLoon & David M. Miller MD, PhD, FAAD for another great Journal Club discussion of the USPSTF recs re: skin cancer screening jamanetwork.com/journals/jama/…

Explore Mohs Micrographic Surgery and Immunotherapy in Non-Melanoma Skin Cancer with leading experts Dr. Miller David M. Miller MD, PhD, FAAD and Dr.Patel! Register now for Monday, June 26th at 7:00 PM ET: medlearninggroup.com/cme-programmin… #Virtual #CME #Immunotherapy #MedTwitter #MedLearningGroup

Thanks to Howard Kaufman, David M. Miller MD, PhD, FAAD, Isaac Brownell, Nikhil Khushalani, Laura Ferris, Ryan Sullivan, Emily Kim, MD et al for a great #SoCO Journal Club discussion on data from S1616, recently published in Nature Medicine. nature.com/articles/s4159… e #Melanoma #Immunotherapy

What’s the latest data on Mohs surgery for invasive melanoma? Check out this Perspectives on the Science piece in #JoCO journalofcutaneousoncology.io/perspectives/v… #Melanoma #Cancer #mohs #derm

Does more frequent surveillance imaging improve patient outcomes in stage III melanoma? Check out the Perspectives on the Science article by Kevin Emerick and David M. Miller MD, PhD, FAAD doi.org/10.59449/joco.….

Moh's surgery is one option for patients with invasive melanoma. Check out this Perspectives on the Science article to read more about it: doi.org/10.59449/joco.…

Merkel Cell Carcinoma is a rare skin cancer with the potential for recurrence and poor patient outcomes. Check out this Perspectives on the Science article that examines the role of post-operative immunotherapy for MCC: doi.org/10.59449/joco.…

Tumor-Infiltrating lymphocyte #TIL therapy is a new FDA-approved option for patients with advanced #melanoma. In this #JoCO editorial, the authors reflect on the recent approval of the first cellular therapy for melanoma. doi.org/10.59449/joco.…

Check out this Journal of Cutaneous Oncology editorial, in which the authors reflect on the recent approval of the first cellular therapy for melanoma. doi.org/10.59449/joco.…